Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study

Fig. 5

Individual SDAI responses (patients achieving early [IP week 24] sustained [through IP week 52b] SDAI remission). Each row represents an individual patient in the intent-to-treat population. For parts A, B, and C, patients received SC abatacept QW + MTX during the IPc. For part D, patients received abatacept placebo + MTX during the IP and continued the same randomized treatment in the DE period. BL, baseline; DE, de-escalation; EOW, every other week; IP, induction period; MTX, methotrexate; QW, once-weekly; SC, subcutaneous; SDAI, Simplified Disease Activity Index. aPart 1: abatacept EOW + MTX for 24 weeks; part 2: abatacept placebo + MTX for 24 weeks. bDefined as remission at both weeks 40 and 52. cOf the 56 patients from the abatacept + MTX arm who achieved sustained SDAI remission at weeks 24, 40, and 52 during the IP, SDAI status was unknown for four patients during the DE period of the study (data not shown)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us